Phase 2 Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel Study to Assess the Safety and Efficacy of Inhaled Cannabis in Veterans for Treatment of Posttraumatic Stress Disorder (PTSD)
Several preliminary studies suggest that cannabis may treat PTSD symptoms. Building off of our previous MJP1 study, this current study aims to re-examine use of inhaled cannabis for treatment of PTSD using a larger sample size, a parallel design, and methods to mitigate placebo response. This Phase 2 multicenter randomized placebo-controlled, double-blind study will assess the safety and efficacy of inhaled cannabis (high THC) versus placebo to manage PTSD symptoms and pain among approximately 320 Veterans in an outpatient setting. The study will be conducted in Michigan and three other sites in the U.S..
- Current Status: Planning
- Sponsor: MAPS
- Funded by: Michigan Veteran Marijuana Research Grant Program; Press Release
- Redacted MJP2 Study Protocol
-
Phase 2 Study of Cannabis for Veterans with PTSD (MJP2) Continued Partial Clinical Hold Response
-
Statement on Clinical Treatment Practice using Cannabis to Treat Patients with Symptoms of Posttraumatic Stress Disorder (PTSD)
-
July 2022 Progress Report for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
-
Phase 2 Study of Cannabis for Veterans with PTSD (MJP2) Regulatory Correspondences with FDA
-
April 2022 Progress Report for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
-
January 2022 Quarterly Performance Report for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
-
MAPS Awarded $12.9 Million Grant from Michigan to Expand Cannabis Research for Veterans with PTSD
-
FDA Places a Partial Clinical Hold on MAPS Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)